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Abstract
Fifteen percent of couples are globally estimated to be infertile, with up to half of these cases attributed to male infertility. 
Reactive oxidative species (ROS) are known to damage sperm leading to impaired quantity and quality. Although not 
routinely assessed, oxidative stress is a common underlying pathology in infertile men. Antioxidants have been shown 
to improve semen analysis parameters by reducing ROS and facilitating repair of damage caused by oxidative stress, 
but it remains unclear whether they improve fertility. Carnitines are naturally occurring antioxidants in mammals and 
are normally abundant in the epididymal luminal fluid of men. We conducted a systematic review and meta-analysis 
to evaluate the safety and efficacy of carnitine supplementation for idiopathic male infertility. We searched ClinicalKey, 
ClinicalTrials.gov, Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, PubMed and ScienceDirect 
for relevant studies published from 1 January 2000 to 30 April 2020. Of the articles retrieved, only eight randomised 
controlled trials were identified and included. Analysis showed that carnitines significantly improve total sperm 
motility, progressive sperm motility and sperm morphology, but without effect on sperm concentration. There was no 
demonstrable effect on clinical pregnancy rate in the five studies that included that outcome, although patient numbers 
were limited. Therefore, the use of carnitines in male infertility appears to improve some sperm parameters but without 
evidence of an increase in the chance of natural conception.
Lay summary
Although male infertility affects 1:15 men, there is no obvious reason in the vast majority of cases. Reactive oxidative 
species (ROS) are highly active molecules containing oxygen and are natural byproducts of normal metabolism. However, 
high concentrations of ROS have been shown to damage sperm, which negatively impacts a couple’s ability to conceive. 
Carnitines are natural antioxidants found in the body that counterbalance the damaging effects of ROS. We conducted a 
comprehensive review of published studies to assess whether carnitine supplements are safe and effective in improving 
sperm quality and pregnancy rates. Our analysis shows that carnitines improve sperm swimming and production of 
normal-shaped sperm cells but do not affect sperm count or pregnancy rates, although there are only a few studies and 
scientific evidence is limited. Whilst it is possible that carnitines may benefit male infertility, more evidence is required 
regarding chances of pregnancy after carnitine therapy.
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Introduction
Infertility is the inability to conceive naturally within 1 
year for a sexually active couple not using contraception 
(Rowe et  al. 2000, World Health Organization 2020). 
Worldwide, 15% of couples are estimated to be infertile 
and approximately 50% of these cases are due to male 
factor, either as the sole underlying cause or a contributory 
factor (Agarwal et al. 2015). Diagnosis of male infertility 
usually follows semen analysis. The results may show 
abnormal semen parameters such as oligozoospermia, 
asthenozoospermia and teratozoospermia or a 
combination of these, or a complete absence of sperm 
in the ejaculate (azoospermia), which is identified in 
10–15% of infertile men (Rowe et al. 2000, Gudeloglu & 
Parekattil 2013, Colpi et al. 2018). Notably, up to 75% of 
male infertility is thought to be idiopathic (i.e. with no 
cause identified) (Punab et al. 2017).
Oxidative stress (OS) occurs when there is an 
overproduction of oxidative free radicals and ROS, 
which damage spermatozoa and cause male infertility 
by impairing both the structure and function of sperm 
(Aitken et  al. 2003, Aitken & Baker 2006, Valko et  al. 
2007, Venkatesh et  al. 2011, Agarwal et  al. 2014). 
Although the exact mechanism(s) of OS in reducing 
sperm quality is unknown, it is widely acknowledged 
that depleted intracellular ATP levels, insufficient 
axoneme phosphorylation and lipid peroxidation of the 
cell membrane manifests as poor motility and sperm 
dysfunction, including reduced ability of sperm to fertilise 
the oocyte (Storey 1997, Gomez et al. 1998, Valko et al. 
2007). Sperm are vulnerable to OS as they have minimal 
cytoplasm and endogenous antioxidant protection 
(Martins da Silva 2019). This leads to the production 
of malondialdehyde (MDA) and 4-hydroxynonenal 
(4HNE), which oxidises the lipid membrane and causes 
fragmentation of both nuclear and mitochondrial DNA 
in sperm (de Lamirande & Gagnon 1992, Kodama et al. 
1997, Gomez et  al. 1998, Aitken et  al. 2012, Iommiello 
et al. 2015).
There are currently no clinically established 
treatments available for unexplained male infertility 
(Martins da Silva et al. 2017). Empirical medical treatments 
such as human menopausal gonadotrophin (hMG)/
human chorionic gonadotrophin (hCG), androgen, 
antioestrogens (clomiphene and tamoxifen), prolactin 
inhibitors (bromocriptine), and steroids have been used. 
However, beneficial effects on semen parameters are not 
proven (Isidori et al. 2006, Jungwirth et al. 2012). Lifestyle 
modification advice such as smoking, alcohol cessation 
and weight reduction programmes are therefore the 
mainstay of managing male infertility, before progressing 
to assisted reproduction. Vitamin and dietary supplements 
are widely marketed to improve male reproductive health 
and have gained considerable popularity in recent years. 
However, many formulations are not evidence based 
(Martins da Silva 2019).
Carnitines are naturally occurring compounds in 
mammals (Bremer 1983, Reuter & Evans 2012). Primary 
sources of carnitines are through dietary intake, de novo 
biosynthesis, and renal tubular reabsorption (Reuter & 
Evans 2012). Foods rich in carnitines include red meats, 
fish, poultry and dairy products (Steiber et al. 2004). Aside 
from dietary consumption, approximately 25% of total 
body carnitine is synthesised by the body from the essential 
amino acids lysine and methionine (Vaz & Wanders 2002, 
Shekhawat et  al. 2013). Endogenous plasma and tissue 
concentrations of carnitines are preserved at relatively 
precise limits to facilitate mitochondrial and peroxisomal 
fatty acid oxidation (Bremer 1983, Reuter & Evans 2012). 
L-carnitine facilitates the β-oxidation of long-chain fatty 
acids, and in its active form of L-acetylcarnitine, is a 
vital antioxidant that protects the sperm mitochondria 
from oxidative stress (Kerner & Hoppel 1998, Russo et al. 
2000, Abdelrazik et al. 2009). Carnitines participate in the 
metabolism of branch-chain amino acids and stabilise 
cellular membranes (Shalev et al. 1986, Adeva-Andany et al. 
2017) and can also act as free radicle scavengers, thereby 
increasing antioxidative capabilities in spermatozoa 
resulting in reduction of OS (Balercia et al. 2005, Dokmeci 
2005, Adewoyin et al. 2017). In vitro, addition of carnitine 
to culture media increases sperm motility and vitality 
(Tanphaichitr 1977, Banihani et al. 2014). Notably, men 
with abnormal semen parameters have been reported to 
have significantly lower carnitine serum levels (Zopfgen 
et al. 2000, Mongioi et al. 2016). In this review we have 
aggregated and analysed currently available data from 
clinical trials of L-carnitine and/or L-acetylcarnitine in 
idiopathic male infertility to determine whether carnitine 
supplements indeed improve sperm quality, and therefore 
male reproductive potential, in couples with male factor 
infertility (Haje & Naoom 2015, Moolenaar et al. 2015).
Materials and methods
Our study is based on the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses Protocols 
(PRISMA-P) and the systematic review is reported 
according to PRISMA guidelines (Moher et  al. 2015, 
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Shamseer et al. 2015). The study protocol is registered in 
PROSPERO (CRD42020181104).
Eligibility criteria
Analysis specifically included only Randomised 
Controlled Trials (RCTs). The RCTs had to be human 
studies with male patients between the ages of 18 and 65, 
with abnormal semen characteristics according to WHO 
normative ranges (2010) and treated with L-carnitine 
and/or L-acetyl-carnitine (World Health Organization 
2010). Studies required at least one control group treated 
with placebo or without treatment.
Reviews, commentaries, observational studies, 
retrospective studies, quasi-randomised trials, case series 
and case reports were excluded. We also excluded literature 
with animal studies, laboratory and in vitro studies, 
female factor infertility, undiagnosed patients, infertility 
<1 year, couples with no regular sexual intercourse and 
other causes of male infertility not related to abnormal 
semen analysis.
Information sources
Literature search strategies were developed using 
medical subject heading (MeSH) terms and text relating 
to the impact of L-carnitine and L-acetylcarnitine on 
male reproductive potential. We searched ClinicalKey, 
ClinicalTrials.gov, Cochrane Central Register of 
Controlled Trials (CENTRAL), EMBASE, MEDLINE, 
PubMed and ScienceDirect thoroughly according to 
PRISMA guidelines (Moher et  al. 2015, Shamseer et  al. 
2015). The literature search was limited to the English 
language and published between 1 January 2000 and 
30 April 2020. Articles were also sourced by screening 
through the references of included studies or relevant 
reviews during the selection process.
Search strategy
Our MeSH terms were ‘male infertility’ or ‘male 
reproductive potential’ or ‘male subfertility’ or 
‘spermatozoa’ or ‘asthenozoospermia’ or ‘oligospermia’ 
or ‘oligoasthenozoospermia’ or ‘teratozoospermia’ or 
‘DNA damage’ or ‘oxidative stress and ‘Carnitine’ or 
‘Levocarnitine’ or ‘L-carnitine’ or ‘L-acetylcarnitine’ or 
‘L-acetyl Carnitine’ or ‘L-acetyl-carnitine’ or ‘L-acetyl 
Carnitine’ or ‘Levoacetylcarnitine’ or ‘Levo-acetyl-
carnitine’ or ‘Levoacetyl Carnitine’ or ‘Levo-acetyl 
Carnitine’ or ‘Acetyl-L-carnitine’ or ‘Acetyl L-carnitine’ 
or ‘Acetyl-L Carnitine’ or ‘Acetyl-Levocarnitine’ or 
‘Acetyl Carnitine’.
Data management and collection
Covidence was used to filter duplicates and conduct the 
systematic review data collection process (Veritas Health 
Innovation). The selection was performed according to 
PRISMA guidelines (Moher et  al. 2015, Shamseer et  al. 
2015). All available pieces of literature were thoroughly 
screened using the inclusion and exclusion criteria through 
Covidence (Veritas Health Innovation). Literature was 
first screened by title and abstract. Full-text articles that 
fulfilled the inclusion criteria were then reviewed. If two or 
more reports had repeated data, the study with the largest 
sample size, most extended follow-up, and most specific 
intervention and outcomes were selected. The screening 
and selection process was carried out by two independent 
review authors simultaneously (Khaw and Wong) using 
a standardised form to include study characteristics such 
as methodology, number of participants, demographics 
of participants, detailed test and control interventions, 
primary and secondary outcomes of the studies, the effect 
of treatment and risk of bias. Missing data were requested 
from study authors. Any discrepancies were resolved 
through consensus.
Risk of bias in individual studies
The Cochrane Collaboration’s tool for assessing the 
risk of bias in randomised trials was used to determine 
the six domains of bias (Higgins et  al. 2011). Two 
independent review authors conducted this assessment 
(Khaw and Wong) and any discrepancies were resolved 
through consensus. Articles were assessed for bias based 
on the following aspects: random sequence generation, 
allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete 
outcome data, selective reporting and other bias (Higgins 
et al. 2011). Each aspect was then classified as high, low, or 
unclear risk of material bias (Higgins et al. 2011). The risk 
of bias assessment chart was then generated using Review 
Manager (RevMan) 5.4 software (The Nordic Cochrane 
Centre 2014).
Data synthesis
We then carried out a descriptive analysis of included 
studies focusing on the methodology of the study, 
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type and details of the intervention, target population 
demographics, primary outcomes, secondary outcomes, 
adverse outcomes and intervention effects. A meta-analysis 
was conducted for studies with the same intervention and 
comparator with equal outcome measures. For the meta-
analysis, we conducted a random-effects meta-analysis 
using risk ratios for dichotomous outcomes and mean 
differences with s.d. The raw mean differences were used 
instead of standardised mean differences, as all studies 
used the same continuous outcomes and units of measure. 
We then used the statistical significance of 95% CIs and 
P-values for each outcome. Where there were results from 
multiple durations of therapy, the results after the most 
prolonged period of treatment was used. Higgins’s I2 test 
statistic (>50% indicative of substantial heterogeneity) 
was utilised to assess heterogeneity among the studies. 
Cochran’s Q test was not used to analyse heterogeneity 
as there were only small numbers of available studies. 
We then proceed with a stratified meta-analysis for 
study quality, trial size, concealment of allocation, 
blind adjudication of events, analysis according to the 
intention-to-treat principle, and intervention method. 
Assessment evidence of publication bias was carried 
out for the included studies and plots were generated 
to visually inspect the data through a funnel plot 
generated by RevMan 5.4 software (The Nordic Cochrane 
Centre 2014). In study outcomes that had substantial 
heterogeneity, the data were also synthesised through a 
narrative and qualitative approach. 
The s.d. from Sigman et  al. (2006) was 
calculated according to the Cochrane Handbook for 
Systematic Reviews of Interventions section 6.5.2.3(3) 
(Higgins et al. 2019).
Overall quality of evidence
The quality and consistency of each comparison was 
assessed using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
guidelines through GRADEpro (Balshem et  al. 2011, 
Schünemann et  al. 2013, Evidence Prime 2015). 
The strength of evidence for critical and essential 
outcomes was rated based on study design, risk of bias, 
consistency, limitations, directness, reporting precision 
and publication bias (Balshem et al. 2011, Schünemann 
et  al. 2013, Evidence Prime 2015). Table 1 shows a 
summary of the included studies and their GRADE 




The search strategy identified 1176 citations dated 1 
January 2000 to 30 April 2020. After 440 duplicates 
were removed, 736 abstracts were assessed. Six hundred 
and ninety-eight records were excluded as they did not 
meet inclusion criteria. Thirty-eight full-text articles 
were searched for eligibility according to inclusion 
and exclusion criterion. All included studies were 
of randomised controlled trials without cross over. 










of evidenceRisk with placebo or 
no treatment, range
Risk with carnitine








2.04 lower to 
7.44 higher
– 438 6 RCTs ⊕⊝⊝⊝ VERY LOWa,b,c
Total sperm 
motility
3.3–43.4% MD 10.72% 
higher
3.94 higher to 
17.5 higher
– 459 7 RCTs ⊕⊕⊝⊝ LOWa,c
Progressive 
sperm motility
4–24.41% MD 9.82% 
higher
2.01 higher to 
17.62 higher
– 231 3 RCTs ⊕⊕⊝⊝ LOWa,c
Normal sperm 
morphology
1.39–32.73% MD 2.41% 
higher
0.79 higher to 
4.03 higher




113 per 1000 116 per 1000 61–221 1.03 (0.54–1.96) 301 5 RCTs ⊕⊕⊝⊝ LOWa,b
The population was men with abnormal semen characteristics. The intervention was l-carnitine and/or l-acetylcarnitine. The table compares placebo or no 
treatment. The outcomes measured were semen analysis parameters; clinical pregnancy; adverse events in a clinic or hospital.
aLack of blinding; bCrosses the line of no effect; cHiggins’s I2 test >50%.
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We excluded Lenzi 2003 as it had a cross-over design (Lenzi 
et al. 2003). A total of eight studies were included in the 
review and the findings from seven studies were pooled 
into a meta-analysis (Cavallini et  al. 2004, Lenzi et  al. 
2004, Balercia et al. 2005, Sigman et al. 2006, Dimitriadis 
et  al. 2010, Mehni et  al. 2014, Haje & Naoom 2015, 
Tsounapi et  al. 2018). The data by Cavellini   et  al. was 
excluded from the meta-analysis as the authors reported 
their results as medians and interquartile ranges rather 
than means and s.d. (Cavallini et  al. 2004). Our search 
process is summarised in the PRISMA flowchart (Fig. 1).
The included articles were assessed based on seven 
aspects: random sequence generation, allocation 
concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome 
data, selective reporting and other bias (Figs 2 and 3). 
Where additional information was required, the study 
authors were contacted but this was unsuccessful. Overall, 
none of the included studies explicitly mentioned the 
method of randomisation (Cavallini et  al. 2004, Lenzi 
et al. 2004, Balercia et al. 2005, Sigman et al. 2006, Mehni 
et al. 2014, Dimitriadis et al. 2010, Haje & Naoom 2015, 
Tsounapi et al. 2018). Hence, all literature had an unclear 
risk of selection bias in this aspect. The majority of articles 
also had unclear risks of detection bias as the process of 
assessment was not reported in detail (Lenzi et al. 2004, 
Sigman et al. 2006, Dimitriadis et al. 2010, Mehni et al. 
2014, Haje & Naoom 2015, Tsounapi et al. 2018).
One study (Tsounapi et al. 2018) was five-armed, four 
studies (Balercia et al. 2005, Dimitriadis et al. 2010, Mehni 
et  al. 2014, Haje & Naoom 2015) were four-armed, one 
study (Cavallini et  al. 2004) was three-armed, and two 
studies (Lenzi et al. 2004, Sigman et al. 2006) were two-
armed. The total duration of treatment ranged from 3 
months (Dimitriadis et al. 2010, Mehni et al. 2014, Haje & 
Naoom 2015, Tsounapi et al. 2018) to 6 months (Cavallini 
et al. 2004, Lenzi et al. 2004, Balercia et al. 2005, Haje & 
Naoom 2015) while follow-up time varied between from 
3 months (Mehni et al. 2014) to9 months (Cavallini et al. 
2004, Balercia et al. 2005). Table 2 shows an overview of 
the included studies.
Population
Our meta-analysis only included studies with idiopathic 
male infertility. The participants were treated with 
carnitine supplementation, placebo or did not receive 
any treatment. Six studies (438 men) recorded sperm 
concentration and morphology, seven studies (459 
men) reported total sperm motility and three studies 
(231 men) evaluated the progressive sperm motility 
after carnitine therapy. Only four studies (252 men) 
reported pregnancy outcomes following carnitine 
supplementation. All participants were between the 
ages of 18 and 65 with infertility of more than 1 year. 
Figure 1 PRISMA flowchart. Figure 2 Risk of bias summary.
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A study by Cavallini et al. (2004) was also included in 
our systematic review, but not in the meta-analysis, as 
their results were recorded in medians and interquartile 
ranges. Their study also enrolled men with varicocele 
but only the results from men with idiopathic 
male infertility were included in our review (Cavallini 
et al. 2004).
Interventions
Data included in our analysis compared l-carnitine (LC) 
and/or l-acetylcarnitine (LAC) to placebo or no treatment. 
Four studies (Cavallini et al. 2004, Lenzi et al. 2004, Balercia 
et al. 2005, Sigman et al. 2006) compared LC and LAC to 
placebos, five studies compared LC to placebo (Balercia 
et al. 2005, Mehni et al. 2014, Haje & Naoom 2015) or no 
treatment (Dimitriadis et al. 2010, Tsounapi et al. 2018) 
while only one study (Balercia et al. 2005) compared LAC 
to placebo.
Outcomes
The primary outcomes for our review are sperm 
concentration, total sperm motility, progressive sperm 
motility, sperm morphology, pregnancy rate and live birth 
rate. We also included sperm DNA damage and adverse 
events such as side effects and miscarriage as secondary 
outcomes. Seven studies (Lenzi et al. 2004, Balercia et al. 
2005, Sigman et al. 2006, Dimitriadis et al. 2010, Mehni 
et  al. 2014, Haje & Naoom 2015, Tsounapi et  al. 2018) 
recorded the total sperm motility while only four studies 
(Cavallini et al. 2004, Lenzi et al. 2004, Balercia et al. 2005, 
Tsounapi et al. 2018) reported progressive sperm motility. 
Sperm concentration and morphology were recorded 
by seven studies (Cavallini et al. 2004, Lenzi et al. 2004, 
Balercia et al. 2005, Dimitriadis et al. 2010, Mehni et al. 
2014, Haje & Naoom 2015, Tsounapi et al. 2018). None of 
the studies included DNA damage assessment. Although 
five studies (Cavallini et  al. 2004, Balercia et  al. 2005, 
Sigman et al. 2006, Haje & Naoom 2015, Tsounapi et al. 
2018) reported on pregnancy rate, none included live 
birth or miscarriage data. We contacted the authors where 
details were unclear or if a different statistical approach 
was used in their study; however, we received no response.
Sperm concentration
Seven studies reported the effects of carnitines on sperm 
concentration (Fig. 4) (Cavallini et  al. 2004, Lenzi et  al. 
2004, Balercia et al. 2005, Dimitriadis et al. 2010, Mehni 
et  al. 2014, Haje & Naoom 2015, Tsounapi et  al. 2018). 
Although the study by Cavallini   et  al. reported higher 
sperm concentrations after LC + LAC therapy (20.6%, 
IQR 24.9–15.1%) when compared to a placebo (10.9%, 
IQR 15.1–9.0%), findings were reported as median and 
interquartile range rather than mean and s.d. and no 
statistical analysis was reported (Cavallini et  al. 2004). 
This study was therefore excluded from the meta-analysis.
Overall, our findings showed that carnitines did not 
significantly improve sperm concentration (P > 0.05). 
However, the six studies showed a high heterogeneity 
(MD 2.70, 95% CI −2.04 to 7.44; n = 438, RCT = 6, 
Figure 3 Risk of bias graph.
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P > 0.05, I2 = 97%) (Lenzi et al. 2004, Balercia et al. 2005, 
Dimitriadis et al. 2010, Mehni et al. 2014, Haje & Naoom 
2015, Tsounapi et al. 2018) primarily due to two studies 
with very small s.d. compared to the others (Mehni 
et  al. 2014, Haje & Naoom 2015). A sensitivity analysis 
after removal of these two studies showed homogeneity 
between the remaining studies but the meta-analysis 
still showed no significant effects of carnitines on sperm 
concentration (MD 0.79, 95% CI −0.39 to 1.96; n = 279, 
RCT = 4, P > 0.05, I2 = 0%) (Lenzi et al. 2004, Balercia et al. 
2005, Dimitriadis et al. 2010, Tsounapi et al. 2018).
Total sperm motility
Seven studies compared the efficacy of carnitines to 
placebo or no treatment (Lenzi et al. 2004, Balercia et al. 
2005, Sigman et al. 2006, Dimitriadis et al. 2010, Mehni 
et  al. 2014, Haje & Naoom 2015, Tsounapi et  al. 2018). 
Analysis of the mean difference in total sperm motility 
showed that carnitines improved total sperm motility by 
10.72% (95% CI 3.94–17.50; n = 459, RCT = 7, P < 0.05, 
I2 = 97%) (Fig. 5).
The studies showed high heterogeneity. In studies 
comparing LC and LAC to placebo, Balercia  et al. showed 
a significant increase in total sperm motility in all three 
study arms when compared to a placebo (MD 18.75, 95% 
CI 14.78–22.73; n = 30, P < 0.05) (Balercia et  al. 2005). 
However two other studies did not show significant 
differences between the treatment and control groups 
(Lenzi et al. 2004, Sigman et al. 2006). Lenzi  et al. showed 
a mean difference of 1.56 (95% CI −4.48 to 7.60; n = 56, 
P > 0.05), while Sigman  et al. showed a mean difference 
of −7.70 (95% CI −20.68 to 5.28; n = 21, P > 0.05). In 
studies that compared LC to placebo or no treatment, four 
studies (Balercia et al. 2005, Dimitriadis et al. 2010, Mehni 
et  al. 2014, Haje & Naoom 2015) showed significant 
improvements after receiving LC while one study 
(Tsounapi et al. 2018) reported no significant differences. 
Balercia et al. (2005) was the only study that assessed LAC 
treatment alone.
A detailed statistical analysis is shown in Fig. 5.
Progressive sperm motility
Four studies showed an increase in progressive sperm 
motility after carnitine when compared to control groups 
(Cavallini et al. 2004, Lenzi et al. 2004, Balercia et al. 2005, 
Tsounapi et  al. 2018). Overall, carnitines significantly 
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infertility (MD 9.82, 95% CI 2.01, 17.62; n = 231, P < 0.05) 
(Fig. 6).
This outcome also showed high heterogeneity 
(I2 = 94%). Balercia et  al. (2005) showed significant 
improvement in progressive sperm motility in all LC, LAC 
and LC + LAC therapy groups (MD 16.02, 95% CI 11.98–
20.06; n = 30, P < 0.05). Tousnapi  et al. (2018) reported a 
significant increase in progressive sperm motility after LC 
therapy (MD 2.00, 95% CI 0.93–3.07; n = 86, P < 0.05). 
Lenzi et al. (2004) did not show a significant increase in 
progressive sperm motility after LC + LAC therapy (MD 
0.59, 95% CI −5.30 to 6.48; n = 56, P > 0.05). Cavallini 
et  al. (2004) reported an increase in progressive sperm 
motility after LC + LAC therapy (23.6%, IQR 28.9–16.0%) 
when compared to controls (13.2%, 18.6–9.0%) but no 
raw data or P-values were provided to draw a statistically 
significant conclusion.
Sperm morphology
The results of sperm morphology were recorded by seven 
studies (Cavallini et  al. 2004, Lenzi et  al. 2004, Balercia 
et al. 2005, Dimitriadis et al. 2010, Mehni et al. 2014, Haje 
& Naoom 2015, Tsounapi et al. 2018). Overall, our results 
showed a significant improvement in sperm morphology 
(P < 0.05) as seen in Fig. 7.
This outcome also had a high heterogeneity 
(I2 = 91%). Balercia et al. (2005) documented a significant 
improvement of 9.29% when compared to a placebo 
(MD 9.29, 95% CI 6.51–12.06; n = 30, P < 0.05). 
Lenzi et  al. (2004) showed no significant differences 
between the treatment and control groups after LC + LAC 
therapy. Among the remaining studies of treatment after 
LC, only the study by Haje and Naoom (2015) showed 
a significant improvement (MD 2.14, 95% CI 1.99–2.29; 
n = 49, P < 0.05) in sperm morphology; while three 
other studies (Dimitriadis et al. 2010, Mehni et al. 2014, 
Tsounapi et  al. 2018) recorded no significant changes. 
Cavallini et al. (2004) recorded an improvement of sperm 
morphology in their study after LC + LAC therapy (27.3%, 
IQR 32.0–22.6% vs 15.3%, IQR 22.0–12.1% in the placebo 
group) but the data provided is not sufficient for a test of 
statistical significance.
Clinical pregnancy rate
A total of five RCTs were analysed for their reported 
pregnancies and four studies were consolidated into a 
meta-analysis. There was low heterogeneity (I2 = 0%) and 
some concern with the risk of bias. The meta-analysis (Fig. 
8) showed that there was no significant improvement in 
pregnancy rates when compared to control groups (RR 
1.17, 95% CI 0.55–2.46; n = 252, RCT = 4, P > 0.05).
In patients treated with a combination of LC and LAC, 
Cavallini et al. (2004) showed a significant improvement 
in pregnancy rate (X2 = 20.795, P < 0.01) when compared 
to controls. In contrast, the three other studies (Lenzi et al. 
2004, Balercia et al. 2005, Sigman et al. 2006) did not show 
significant differences between the two groups (RR 1.89, 
95% CI 0.67–5.36; n = 106, RCT = 3, P > 0.05, I2 = 0%). 
Figure 4 Forest plot of comparison for sperm concentration.
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Patients treated with either LC (RR 0.73, 95% CI 0.28–
1.87; n = 165, RCT = 3, P > 0.05, I2 = 0%) or LAC (RR 0.67, 
95% CI 0.13–3.44; n = 30, RCT = 1, P > 0.05) did not show 
any significant changes in pregnancy rates in comparison 
to their control groups (Balercia et  al. 2005, Haje & 
Naoom 2015, Tsounapi et  al. 2018). Haje and Naoom 
(2015) studied the effect of carnitine supplementation 
in patients undergoing ICSI and reported no significant 
increase in pregnancy rates.
Overall, the results were imprecise as there were very 
few events and thus confidence intervals were wide. 
Moreover, the quality of evidence is also low.
Adverse events
Six studies did not report adverse events (Lenzi et al. 2004, 
Balercia et al. 2005, Dimitriadis et al. 2010, Mehni et al. 
2014, Haje & Naoom 2015, Tsounapi et al. 2018). Sigman 
et al. (2006) confirmed that there were no adverse events 
in their study. Cavallini et al. (2004) reported four cases 
of mild euphoria (two in the LC + LAC group and two in 
control groups). Their study also recorded two cases of 
gastrointestinal side effects (mild epigastria and nausea) 
from both the treatment and control groups. However, 
these side effects were reported as negligible as they did 
not result in therapy suspension. None of the studies 
included data related to miscarriage.
Carnitine versus other arms in the included studies
Further studies were identified that compared carnitine to 
other compounds, rather than placebo or no treatment. 
They were therefore not included in the meta-analysis but 
are summarised in Table 3.
Discussion
Several published studies have reported that carnitines 
have beneficial effects on improving sperm quality in 
men with idiopathic male infertility (Steiber et al. 2004, 
Isidori et al. 2005, Isidori et al. 2006, Mongioi et al. 2016, 
Smits et  al. 2019). Notably, concentrations of carnitine 
have also been documented to be higher in the sperm 
and seminal plasma of fertile men, compared to men 
with abnormal semen parameters (Zopfgen et  al. 2000, 
Banihani et al. 2014, Mongioi et al. 2016, Smits et al. 2019). 
The scientific rationale behind this is a vital role played by 
carnitines during spermatogenesis (Jeulin & Lewin 1996, 
Agarwal & Sekhon 2011, Aliabadi et al. 2012). Carnitines 
Figure 5 Forest plot of comparison for total sperm motility.
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are concentrated in the epididymal luminal fluid (Jeulin 
& Lewin 1996), and likely to be associated with sperm 
maturation. Carnitines also scavange free oxygen radicles 
and ROS, thus protecting against OS, as well as aiding 
cellular repair in mitochondria during β-oxidation of 
long-chain fatty acids (Fritz 1963, Steiber et  al. 2004, 
Reuter & Evans 2012, Smits et al. 2019). However, whilst 
improved semen characterisitics have been reported, 
Figure 6 Forest plot of comparison for progressive sperm motility.
Figure 7 Forest plot of comparison for normal sperm morphology.
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very few studies have recorded pregnancy outcomes after 
treatment of infertile men with carnitines, and none have 
considered live birth as a primary outcome (Zini et  al. 
1993, Shekarriz et al. 1995, Hakonsen et al. 2011, Poljsak 
2011, Moolenaar et al. 2015).
This meta-analysis presents evidence supporting 
the improvement of sperm parameters with carnitine 
supplementation. Carnitines significantly improve total 
sperm motility (+10.72%), progressive sperm motility 
(+9.82%) and sperm morphology (+2.41%) (Cavallini 
et al. 2004, Lenzi et al. 2004, Balercia et al. 2005, Sigman 
et al. 2006, Dimitriadis et al. 2010, Mehni et al. 2014, Haje 
& Naoom 2015, Tsounapi et  al. 2018). There does not 
appear to be a positive effect of carnitine supplementation 
on sperm concentration (Cavallini et al. 2004, Lenzi et al. 
2004, Balercia et al. 2005, Dimitriadis et al. 2010, Mehni 
et  al. 2014, Haje & Naoom 2015, Tsounapi et  al. 2018). 
However, it is notable that the studies are characterised by 
high heterogeneity, and the quality of the evidence was 
low (total sperm motility, progressive sperm motility and 
sperm morphology) or very low (sperm concentration) 
when assessed through GRADEpro (Table 1).
The data indicate that carnitine does not significantly 
improve pregnancy rates in infertile couples with male 
infertility, despite improvements in sperm motility and 
morphology. However, natural conception was not a 
primary outcome in most studies, indeed most did not 
follow-up until pregnancy. Therefore, more evidence is 
required to study the effects of carnitines on pregnancy 
outcomes. Although multiple attempts have been made 
to encourage RCTs to report on fertility outcomes, very 
few RCTs achieve this in studies relating to male infertility 
(Tournaye, 2006). Nonetheless, two recently reported large 
RCTs showed that folic acid and zinc supplements (FAZST) 
or combination antioxidant treatment including Vitamin 
C, Vitamin E, folic acid, selenium, zinc, and l-carnitine 
(MOXI trial) did not improve clinical pregnancy or live 
birth rates when compared to placebo (Schisterman et al. 
2020, Steiner et al. 2020).
Our findings are consistent with previously published 
systematic reviews researching the efficacy and safety of 
antioxidants in idiopathic male infertility. Two systematic 
reviews of empirical dietary and/or supplementary 
intervention recorded improved total sperm motility, 
Figure 8 Forest plot of comparison for clinical pregnancy.
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progressive sperm motility and sperm morphology (Salas-
Huetos et al. 2018, Omar et al. 2019). However, it is notable 
that our findings of effects on total sperm motility and 
morphology differ from a recent meta-analysis of carnitines 
in men with idiopathic oligoasthenoteratozoospermia 
conducted by Zhang et al. (2020). Their systematic review 
included studies of carnitine plus other antioxidants/
compounds and one study that used active controls 
(Zhang et  al. 2020). In contrast, we selected studies of 
carnitine-only treatment vs non-active controls so these 
studies were excluded during our full-text screening. 
We also included additional studies from other database 
searches (Zhang et al. 2020). However, the other authors 
similarly commented on inconsistent data and high 
heterogeneity amongst the published trials.
A major limitation of this systematic review, and 
others, is the inability to assess robustly the effect of 
carnitines on natural conception and pregnancy outcomes 
as this has not been comprehensively studied to date. 
Critically, our findings in regards to pregnancy rates did 
not support carnitine supplementation as an intervention 
for male infertility, which disagrees with Zhang et al. and 
is reflective of the different study data included (Zhang 
et al. 2020).
Conclusion
Overall, our systematic review shows that carnitine 
supplementation can improve sperm motility and 
morphology. However, there were only eight randomised 
controlled trials that specifically compared carnitine(s) 
to placebo or no treatment and study outcomes had 
high heterogeneity and were derived from low-quality 
evidence (Table 1). The majority of studies included 
found that carnitines were most effective in men with 
severe idiopathic infertility (Cavallini et  al. 2004, 
Balercia et  al. 2005, Sigman et  al. 2006, Mehni et  al. 
2014), supporting their use as a potential treatment. 
However, whilst it is accepted that gains in male fertility 
are likely to be seen with improvement in total motile 
count, particularly when at the lower end of the range 
(Hamilton et  al. 2015), studies included in this meta-
analysis have not demonstrated increase in chance of 
conception, pregnancy and live birth with carnitine 
supplementation. It therefore remains unclear whether 
carnitines are a suitable intervention for idiopathic male 
infertility and randomised placebo‐controlled trials 
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